Sabine Brookman-May, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X:
“ESMO25 | EMBARK Enza+ADT: MFS/OS in HR BCR Prostate Cancer.
Does this set a new SoC?
EMBARK used historic imaging/no PSMA, limiting true stage Dx.
Earlier local treatment partially missed.
Modern staging needs to reshape who truly benefits.”
You can also read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
ESMO 2025 Day 4 Highlights Not to Miss
ESMO 2025 Day 5 Highlights Not to Miss
